About Alveo Technologies
Alveo Technologies is a company based in Alameda (United States) founded in 2014 by Mike Aicher and Lawrence M Blatt. Alveo Technologies has raised $63.61 million across 4 funding rounds from investors including Gates Foundation, Maxim Group and Supply Change Capital. Alveo Technologies offers products and services including Alveo Sense™ Poultry Avian Influenza Test and Alveo Platform. Alveo Technologies operates in a competitive market with competitors including NeuMoDx, GenMark Diagnostics, Biomeme, Sense Biodetection and Bioskryb, among others.
- Headquarter Alameda, United States
- Founders Mike Aicher, Lawrence M Blatt
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website alveotechnologies.com
- Social LinkedIn X
- Legal Name Alveo S.R.O.
- Total Equity Funding$63.61M (USD)
in 4 rounds
- InvestorsGates Foundation
& 2 more
Products & Services of Alveo Technologies
Alveo Technologies offers a comprehensive portfolio of products and services, including Alveo Sense™ Poultry Avian Influenza Test and Alveo Platform.
Rapid molecular tool for detecting avian influenza in poultry samples.
Handheld analyzer for on-site pathogen testing in various sectors.
Funding Insights of Alveo Technologies
Alveo Technologies has successfully raised a total of $63.61M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $63.61M
- Total Rounds 4
- First Round $47.61M
(Jan 2018)
- Investors Count 3
All 4 funding rounds of Alveo Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | – | Series A | – | – | |
| Mar 2021 | $16M | Series A | – | – | – |
| Nov 2020 | – | Grant | – | – | |
| Jan 2018 | $47.61M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Alveo Technologies
Alveo Technologies has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Maxim Group and Supply Change Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | supplychange.fund | - | |
Financial advisory services are provided across multiple sectors. | 2002 | maximgrp.com | New York, United States | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for Alveo Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alveo Technologies
31 people are tracked at Alveo Technologies (11 in leadership, 3 in board & advisors, 17 in team).
| Name | Role | Group |
|---|---|---|
Mike Aicher | Co-Founder | Leadership |
Lawrence M Blatt | Co-Founder | Leadership |
Shaun Holt | CEO & Chairman | Leadership |
Slava Elagin | CTO | Leadership |
Erik Tyrrell-Knott | Chief Business & Strategy Officer | Leadership |
Mary K. McFillin | Vice President, Product Management | Leadership |
Angie Aquino-Sales | Senior Director, People & Culture | Leadership |
Mariana Heiermann | Senior Director of R&D Operations | Leadership |
Helen Belcastro | VP, Portfolio Planning & Program Management | Leadership |
Raj Limaye | Vice President Of Software Engineering | Leadership |
Ali Coopersmith | Director, Strategic Alliances | Leadership |
Thermo Fisher | Scientific Advisor | Board & advisors |
George Church | Scientific Advisor | Board & advisors |
Michael Marks | Board Member | Board & advisors |
Kelley Tran | Clinical Operations Manager | Team |
Zoya Zulfiqar | Program Manager Quality Assurance | Team |
Hexiang Liu | Data Scientist | Team |
Renee Argishti | Sr. Quality Assurance Associate | Team |
Jenny Hirschfeld | Quality Control Program Manger | Team |
Joseph Pham | Mechanical Engineer III | Team |
11 more people are available in the full profile.
Complete people profiles for Alveo Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Alveo Technologies
3 dated milestones of Alveo Technologies across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Alveo Technologies is founded.
- Funding First funding round of $47.6M.
- Funding Latest funding round, Series A,.
Competitors of Alveo Technologies
Alveo Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NeuMoDx, GenMark Diagnostics, Biomeme, Sense Biodetection and Bioskryb, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neumodx.com | 2012 | Ann Arbor, United States | $66.04M | 125 | Developer of a platform for low cost molecular testing | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| biomeme.com | 2013 | Philadelphia, United States | $6.2M | 202 | Smartphone-based DNA detection platform is developed for diagnostics. | |
| sense-bio.com | 2014 | Abingdon, United Kingdom | $79.22M | 43 | Provider of point of care molecular diagnostics solutions | |
| bioskryb.com | 2018 | Durham, United States | $11.5M | 21 | Genome amplification systems for DNA sequencing are developed. | |
| targetingone.com | 2015 | Haidian, China | $23.19M | – | Micro-droplet digital PCR and diagnostic reagents are manufactured. | |
| minipcr.com | 2013 | Cambridge, United States | – | 18 | PCR and electrophoresis instruments are developed for laboratory use. | |
| primeradx.com | 2004 | Mansfield, United Kingdom | $19.76M | – | Molecular diagnostic products and platforms are developed for clinical use. | |
| anavasidx.com | 2020 | Seattle, United States | $6M | – | Molecular detectors for COVID-19 detection are manufactured. |
Detailed competitors of Alveo Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Alveo Technologies
The website of Alveo Technologies (alveotechnologies.com) receives about 1.6K visits a month.
- Monthly visits1.6K
▼ 11.5% vs previous month
Websites whose visitors overlap most with Alveo Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
saratechnologies.com | saratechnologies.com | 100% | – | – | – |
a2zremodelingcal.com | a2zremodelingcal.com | 98% | – | – | – |
| promaxo.com | 92% | 2.7K | #5,822,874 | View details | |
prodesignersagency.com | prodesignersagency.com | 89% | – | – | – |
Latest news on Alveo Technologies
Complete news archive for Alveo Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Alveo Technologies
10 companies that operate in the same segment as Alveo Technologies (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Alveo Technologies
Alveo Technologies was founded in 2014 and raised its 1st funding round 4 years after it was founded.
Alveo Technologies is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
Alveo Technologies is a funded company, having raised a total of $63.61M across 4 funding rounds to date. The company's 1st funding round was a Series A of $47.61M, raised on Jan 2018.
Alveo Technologies is an early-stage biotech company developing point of care molecular diagnostic devices. Alveos technology incorporates cloud-based analytics with rapid, point of care molecular testing to create an integrated, connected solution for infectious disease diagnostics.
Alveo Technologies's top competitors include GenMark Diagnostics, NeuMoDx and Bioskryb.
Alveo Technologies offers Alveo Sense™ Poultry Avian Influenza Test and Alveo Platform.
Alveo Technologies has 3 investors. Key investors include Gates Foundation, Maxim Group, and Supply Change Capital.
Alveo Technologies operates through Alveo S.R.O..